摘要
Objective: The aim of our study was to compare the efficacy and toxicities of vinorelbine plus cisplatin(NP) regimen with that of vinorelbine plus capecitabine(NX) regimen in the treatment of anthracycline- and taxane-refractory advanced breast cancer. Methods: Forty-six patients with anthracycline- and taxane-refractory advanced breast cancer were equally randomized into a NP group(n = 23) and a NX group(n = 23). Response rates and toxicities were evaluated after 2 cycles of chemotherapy. Results: The overall response rate were 48.0% in both groups. There were no significant differences in disease control rates(78.0% vs. 83%) or 1-year survival rates(54.6% vs. 55.9%). The main adverse events were bone marrow depression and gastrointestinal reaction, and no significant difference was found in toxicities between the groups. Conclusion: For anthracycline- and taxane-refractory advanced breast cancer, NP and NX regimens exerted similar curative effects with acceptable toxicity.
Objective： The aim of our study was to compare the efficacy and toxicities of vinorelbine plus cisplatin （NP） regimen with that of vinorelbine plus capecitabine （NX） regimen in the treatment of anthracycline- and taxane-refractory advanced breast cancer. Methods： Forty-six patients with anthracycline- and taxane-refractory advanced breast cancer were equally randomized into a NP group （n = 23） and a NX group （n = 23）. Response rates and toxicities were evaluated after 2 cycles of chemotherapy. Results： The overall response rate were 48.0% in both groups. There were no significant differences in disease control rates （78.0% vs. 83%） or 1-year survival rates （54.6% vs. 55.9%）. The main adverse events were bone marrow depression and gastrointestinal reaction, and no significant difference was found in toxicities between the groups. Conclusion： For anthracycline- and taxane-refractory advanced breast cancer, NP and NX regimens exerted similar curative effects with acceptable toxicity.
基金
Supported by a grant from the Key Project of National 12th Five-year Research Program of China(No.2012ZX0903016-002)
关键词
乳腺癌
环类
长春
晚期
紫杉
治疗
顺铂
蒽
capecitabine
vinorelbine
cisplatin
advanced breast cancer
